Startup profile · funding coverage
Canid funding, valuation and investors
Scan-and-go vaccine operations platform for independent pediatric practices.
Keep track of Canid
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$10M · June 2025
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$10M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · New York, NY
Overview
Canid streamlines pediatric vaccine programs by integrating with EHRs to automate ordering, inventory, billing, and public-health reporting. Founded by Pedro Sánchez de Lozada after seeing challenges in his family's pediatric practices, the NYC company raised $10M Series A in June 2025 led by Telescope Partners with FJ Labs and Brooklyn Bridge Ventures participating, bringing total funding to $12.9M. Canid serves 150+ pediatricians across 12 states per Business Wire.
Why Canid is interesting
Vaccines are the second-largest pediatric practice expense yet most clinics break even or lose money — Canid turns a barcode scan into outsourced vaccine ops.
Product & use cases
EHR-integrated platform where pediatricians scan a vaccine barcode and Canid handles inventory, reimbursement, compliance reporting, and outreach automation.
- Outsourced vaccine inventory and billing for small pediatrics
- AI-assisted EHR integration across clinic systems
- Patient outreach to close vaccination gaps
Key facts
- Series A (Jun 2025): $10M; total $12.9M
- 150+ pediatricians, 300K+ children in panels
- Started with COVID vaccines, expanded to all vaccines 2022
- Endpoints News: 69% of pediatricians break even or lose on vaccines
Funding history (newest first)
Series A
2025-06 $10M- Telescope Partners (lead)
- FJ Labs (participant)
- Brooklyn Bridge Ventures (participant)
Source: Read source · businesswire.com
Investors in our directory
Funds linked from Canid's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Vertical focus on vaccine economics with guaranteed payments and inventory risk transfer — not generic practice management.
Pediatric vaccine programs are operationally brutal at small scale; Canid's model only works if reimbursement automation beats in-house staff costs. Expansion depends on EHR integration depth and payer relationships.
-
EHR-native vaccine modules incumbent
Built-in EHR workflows without outsourced inventory.
-
Vaccine distributors (McKesson, etc.) adjacent
Supply chain without full admin automation.
-
Pediatric practice consultants alternative
Manual billing and inventory management.
Notable stories
- Sánchez de Lozada told Endpoints Canid began during COVID vaccine distribution before expanding to routine immunizations in 2022.
- Canid reported a 12% drop in vaccinations across its network Q1 2024 vs Q1 2025 amid broader hesitancy trends.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Canid's financing or category context.
FAQs about Canid
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.